دورية أكاديمية
Technological Advancements in Monoclonal Antibodies.
| العنوان: | Technological Advancements in Monoclonal Antibodies. |
|---|---|
| المؤلفون: | Santos-Neto JF; University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil., Oliveira FO; SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil., Hodel KVS; SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil., Fonseca LMS; SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil., Badaró R; SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil., Machado BAS; University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil.; SENAI Institute of Innovation (ISI) in Advanced Health Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, National Service of Industrial Learning-SENAI, Salvador, Bahia, Brazil. |
| المصدر: | TheScientificWorldJournal [ScientificWorldJournal] 2021 Feb 10; Vol. 2021, pp. 6663708. Date of Electronic Publication: 2021 Feb 10 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Hindawi Publishing Corporation Country of Publication: United States NLM ID: 101131163 Publication Model: eCollection Cited Medium: Internet ISSN: 1537-744X (Electronic) Linking ISSN: 1537744X NLM ISO Abbreviation: ScientificWorldJournal Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York : Hindawi Publishing Corporation Original Publication: Boynton Beach, FL : Scientific World, Inc., c2001- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*therapeutic use , Biosimilar Pharmaceuticals/*therapeutic use , Inventions/*trends , Neoplasms/*drug therapy, Antibodies, Monoclonal/immunology ; Humans ; Immunotherapy/trends ; Neoplasms/immunology |
| مستخلص: | Biopharmaceuticals are innovative solutions that have revolutionized the treatment of important chronic diseases and malignancies. The approval of biosimilar products has become a complex and balanced process, and there are versions of drugs with established biosimilarity that can offer a more accessible treatment option to patients. The objective of this work was to identify the advancement of these technologies by means of patent and article analysis based on technological and scientific prospection. In patent document recovery, Derwent Innovation Index (DWPI) and PatentInspiration databases were used. The research was based on the search of the selected terms in the title, summary, and claims of the documents through a search strategy containing IPC code and keywords. In articles recovery, the Web of Science tool was used in the search of scientific publications dated from the last 5 years. The search resulted in a total of 2295 individual patent documents and 467 families using DWPI database, 769 individual patents and 205 families using PatentInspiration, and 2602 articles using Web of Science database. Additionally, this work describes the number of organizations that contribute to this area, where they are, how much development they have undergone, and the inventors/authors involved. Based on the number of publications registered, there is an important prominence for scientific research in mAbs. In terms of innovation, it is expected that several therapeutic drugs are already under regulatory review, which will allow drugs to be approved over the next few years and will thus generate a continuous flow of new products based on immunotherapies, mAbs, and biosimilar drugs. These drugs have become essential weapons for the treatment of significant diseases, and the increasing trend in the number of related scientific and technological publications contributes to making these therapies available to the greatest number of people. Competing Interests: The authors declare that there are no conflicts of interest. (Copyright © 2021 José F. Santos-Neto et al.) |
| References: | Anticancer Drugs. 2018 Sep;29(8):791-801. (PMID: 29846248) Future Oncol. 2019 Mar;15(7):777-790. (PMID: 30500264) J Toxicol Pathol. 2015 Jul;28(3):133-9. (PMID: 26441475) Appl Microbiol Biotechnol. 2010 Jan;85(4):909-19. (PMID: 19885657) United European Gastroenterol J. 2018 Mar;6(2):310-321. (PMID: 29511561) Oncol Rep. 2021 Jan;45(1):329-336. (PMID: 33200231) Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. (PMID: 28301271) Ther Adv Musculoskelet Dis. 2018 Oct 31;10(12):253-259. (PMID: 30515251) J Pharm Sci. 2020 Jan;109(1):74-103. (PMID: 31173761) Nature. 1975 Aug 7;256(5517):495-7. (PMID: 1172191) J Ren Care. 2015 Mar;41(1):53-61. (PMID: 25348203) MAbs. 2014;6(5):1163-77. (PMID: 25517302) Nat Commun. 2015 Aug 27;6:8072. (PMID: 26311203) J Biomed Sci. 2020 Jan 2;27(1):1. (PMID: 31894001) Eur J Clin Invest. 2020 Apr 20;:e13242. (PMID: 32307698) Ann N Y Acad Sci. 2017 Nov;1407(1):5-16. (PMID: 28905423) Hum Vaccin Immunother. 2015;11(12):2769-76. (PMID: 26211701) Cad Saude Publica. 2007 Feb;23(2):257-67. (PMID: 17221075) Methods Mol Biol. 2012;901:11-32. (PMID: 22723092) Handb Exp Pharmacol. 2019;260:81-141. (PMID: 31820172) Clinicoecon Outcomes Res. 2011;3:29-36. (PMID: 21935330) BioDrugs. 2019 Aug;33(4):353-356. (PMID: 31175631) Front Immunol. 2014 Oct 20;5:520. (PMID: 25368619) JAMA Oncol. 2018 Feb 01;4(2):241-247. (PMID: 28727871) J Crohns Colitis. 2017 Jun 01;11(6):690-696. (PMID: 28130330) BioDrugs. 2020 Apr;34(2):159-170. (PMID: 31792843) ScientificWorldJournal. 2015;2015:842101. (PMID: 25874259) J Mol Graph Model. 2021 Jan;102:107774. (PMID: 33130388) Appl Health Econ Health Policy. 2018 Oct;16(5):653-660. (PMID: 30019138) Trends Biotechnol. 2005 Nov;23(11):553-8. (PMID: 16051388) Rand Health Q. 2018 Mar 30;7(4):3. (PMID: 30083415) J Biomed Mater Res A. 2021 Aug;109(8):1393-1405. (PMID: 33252182) Clin Ther. 2015 Apr 1;37(4):842-57. (PMID: 25704107) MAbs. 2020 Jan-Dec;12(1):1703531. (PMID: 31847708) Lancet Oncol. 2017 Jan;18(1):22-23. (PMID: 28049571) Cell Rep Med. 2020 Oct 29;1(8):100137. (PMID: 33294858) J Food Drug Anal. 2019 Jul;27(3):671-678. (PMID: 31324283) Bull World Health Organ. 2018 Apr 1;96(4):281-285. (PMID: 29695884) J Clin Pharmacol. 2021 Mar;61(3):406-411. (PMID: 33180360) Pharmacoeconomics. 2017 Oct;35(10):1047-1062. (PMID: 28660473) Semin Oncol. 2014 Apr;41 Suppl 3:S13-20. (PMID: 24767632) J Ind Microbiol Biotechnol. 2013 Apr;40(3-4):257-74. (PMID: 23385853) Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv31-36. (PMID: 15827057) Cancer Res. 2020 Feb 1;80(3):524-535. (PMID: 31690671) Health Policy. 2015 Feb;119(2):212-6. (PMID: 25523144) Kidney Int. 2020 Jun;97(6):1196-1207. (PMID: 32305129) J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 15;848(1):8-18. (PMID: 16899415) Diabetes. 2021 Jan;70(1):171-181. (PMID: 33122392) Nat Biotechnol. 2010 Sep;28(9):917-24. (PMID: 20829826) J Diabetes Sci Technol. 2015 Sep 08;10(2):457-62. (PMID: 26350722) Biomed Res Int. 2015;2015:168935. (PMID: 25811022) Cancers (Basel). 2020 Jul 07;12(7):. (PMID: 32645836) Nat Commun. 2020 Jun 12;11(1):2992. (PMID: 32532974) N Engl J Med. 2018 May 24;378(21):2036-2044. (PMID: 29791832) Cancer Sci. 2020 May;111(5):1461-1467. (PMID: 32073704) Thorac Cancer. 2020 Dec;11(12):3641-3644. (PMID: 33073527) Nat Biotechnol. 2012 Mar 25;30(5):447-52. (PMID: 22446692) Clin Immunol. 2020 Oct;219:108555. (PMID: 32771488) Ann Rheum Dis. 2020 Jun;79(6):685-699. (PMID: 31969328) Drug Discov Today. 2014 Jul;19(7):869-81. (PMID: 24239727) Am J Public Health Nations Health. 1936 Dec;26(12):1215-8. (PMID: 18014551) Nat Rev Drug Discov. 2010 Oct;9(10):767-74. (PMID: 20811384) ScientificWorldJournal. 2010 Jun 15;10:1107-20. (PMID: 20563534) Future Oncol. 2014;10(9):1599-609. (PMID: 25145430) Biotechnol Healthc. 2004 Sep;1(4):24-9. (PMID: 23393437) Drug Metab Pharmacokinet. 2019 Feb;34(1):64-70. (PMID: 30600193) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Biosimilar Pharmaceuticals) |
| تواريخ الأحداث: | Date Created: 20210225 Date Completed: 20211025 Latest Revision: 20240330 |
| رمز التحديث: | 20240330 |
| مُعرف محوري في PubMed: | PMC7892242 |
| DOI: | 10.1155/2021/6663708 |
| PMID: | 33628140 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-744X |
|---|---|
| DOI: | 10.1155/2021/6663708 |